Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding the issuance of letter of confirmation in the name of the legal heir for the share certificates reported lost.
Jubilant Pharmova stock gains 6.45% in an overall weak market; here's why
Jubilant Pharmova's share price surged 6.45% after its Radiopharma business received ANDA approval for Technetium Sulfur Colloid Injection. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release under Regulation 30 (LODR) Jubilant Pharmova Ltd - 530019 - Compliance Under Regulation 39(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Compliance under Regulation 39(3) of the SEBI (Listing Obligation and Disclosure Requirements) Regulatio, 2015. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2023 published on October 28, 2023 in MINT (English) and HINDUSTAN (Hindi). Q2FY24 Quarterly Result Announced for Jubilant Pharmova Ltd.
Pharmaceuticals company Jubilant Pharmova announced Q2FY24 results: 1. Financial Results - Consolidated: - Total Revenue for Q2FY24 was Rs 1,680 crore, with a growth of 5% compared to Q2FY23. - Adjusted Revenue for Q2FY24 was Rs 1,704 crore, with a growth of 7% compared to Q2FY23. - Reported EBITDA for Q2FY24 was Rs 252 crore, with a margin of 15%. - Adjusted EBITDA for Q2FY24 was Rs 289 crore, with a margin of 17%. 2. Radiopharmaceuticals: - Revenue for Q2FY24 was Rs 251 crore, accounting for 15% of the company's revenue. - EBITDA margin for Q2FY24 was 53%. 3. Radiopharmacies: - Revenue for Q2FY24 was Rs 490 crore, accounting for 29% of the company's revenue. - EBITDA margin for Q2FY24 was 1%. 4. Allergy Immunotherapy: - Revenue for Q2FY24 was Rs 179 crore, accounting for 11% of the company's revenue. - EBITDA margin for Q2FY24 was 48%. 5. CDMO Sterile Injectables: - Revenue for Q2FY24 was Rs 301 crore, accounting for 18% of the company's revenue. - EBITDA margin for Q2FY24 was 19%. 6. Generics: - Revenue for Q2FY24 was Rs 172 crore, accounting for 10% of the company's revenue. - EBITDA margin for Q2FY24 was (29)%. 7. Drug Discovery Services: - Revenue for Q2FY24 was Rs 115 crore, accounting for 7% of the company's revenue. - EBITDA margin for Q2FY24 was 22%. 8. CDMO - API: - Revenue for Q2FY24 was Rs 165 crore, accounting for 10% of the company's revenue. - EBITDA margin for Q2FY24 was 9%. Result PDF Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release and presentation on Financial Results Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Change in Directorate
Change in Directors. Disclosure as per attachment. Jubilant Pharmova Ltd - 530019 - Unaudited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2023 Alongwith Limited Review Report For The Said Period.
Unaudited standalone & Consolidated financial Results for Q2 FY 2024 Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliance under Reg 39(3) for Loss of Certificate